Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PGM1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PGM1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PGM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PGM1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PGM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PGM1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PGM1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00010 | Colorectum | AD | Glycolysis / Gluconeogenesis | 34/2092 | 67/8465 | 3.63e-06 | 4.34e-05 | 2.77e-05 | 34 |
hsa000101 | Colorectum | AD | Glycolysis / Gluconeogenesis | 34/2092 | 67/8465 | 3.63e-06 | 4.34e-05 | 2.77e-05 | 34 |
hsa000106 | Colorectum | FAP | Glycolysis / Gluconeogenesis | 24/1404 | 67/8465 | 1.05e-04 | 9.46e-04 | 5.76e-04 | 24 |
hsa01250 | Colorectum | FAP | Biosynthesis of nucleotide sugars | 13/1404 | 37/8465 | 4.79e-03 | 1.91e-02 | 1.16e-02 | 13 |
hsa000107 | Colorectum | FAP | Glycolysis / Gluconeogenesis | 24/1404 | 67/8465 | 1.05e-04 | 9.46e-04 | 5.76e-04 | 24 |
hsa012501 | Colorectum | FAP | Biosynthesis of nucleotide sugars | 13/1404 | 37/8465 | 4.79e-03 | 1.91e-02 | 1.16e-02 | 13 |
hsa012502 | Colorectum | CRC | Biosynthesis of nucleotide sugars | 12/1091 | 37/8465 | 1.66e-03 | 1.20e-02 | 8.16e-03 | 12 |
hsa012503 | Colorectum | CRC | Biosynthesis of nucleotide sugars | 12/1091 | 37/8465 | 1.66e-03 | 1.20e-02 | 8.16e-03 | 12 |
hsa012505 | Esophagus | ESCC | Biosynthesis of nucleotide sugars | 28/4205 | 37/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 28 |
hsa005202 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
hsa0001016 | Esophagus | ESCC | Glycolysis / Gluconeogenesis | 42/4205 | 67/8465 | 2.15e-02 | 4.78e-02 | 2.45e-02 | 42 |
hsa0125012 | Esophagus | ESCC | Biosynthesis of nucleotide sugars | 28/4205 | 37/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 28 |
hsa0052011 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
hsa0001017 | Esophagus | ESCC | Glycolysis / Gluconeogenesis | 42/4205 | 67/8465 | 2.15e-02 | 4.78e-02 | 2.45e-02 | 42 |
hsa000109 | Liver | Cirrhotic | Glycolysis / Gluconeogenesis | 32/2530 | 67/8465 | 1.50e-03 | 7.80e-03 | 4.81e-03 | 32 |
hsa00030 | Liver | Cirrhotic | Pentose phosphate pathway | 16/2530 | 30/8465 | 6.04e-03 | 2.12e-02 | 1.30e-02 | 16 |
hsa0001012 | Liver | Cirrhotic | Glycolysis / Gluconeogenesis | 32/2530 | 67/8465 | 1.50e-03 | 7.80e-03 | 4.81e-03 | 32 |
hsa000301 | Liver | Cirrhotic | Pentose phosphate pathway | 16/2530 | 30/8465 | 6.04e-03 | 2.12e-02 | 1.30e-02 | 16 |
hsa0001022 | Liver | HCC | Glycolysis / Gluconeogenesis | 43/4020 | 67/8465 | 4.26e-03 | 1.29e-02 | 7.15e-03 | 43 |
hsa000302 | Liver | HCC | Pentose phosphate pathway | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PGM1 | SNV | Missense_Mutation | novel | c.231N>G | p.Ile77Met | p.I77M | P36871 | protein_coding | tolerated(1) | benign(0.04) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PGM1 | SNV | Missense_Mutation | novel | c.1106C>T | p.Ala369Val | p.A369V | P36871 | protein_coding | tolerated(0.15) | benign(0.028) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PGM1 | SNV | Missense_Mutation | rs748304901 | c.716N>A | p.Arg239His | p.R239H | P36871 | protein_coding | tolerated(0.56) | benign(0.033) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PGM1 | SNV | Missense_Mutation | novel | c.1198N>T | p.Gly400Cys | p.G400C | P36871 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A73W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
PGM1 | insertion | Nonsense_Mutation | novel | c.116_117insCTTCAAATACAAAGGACTTAAACTGCTTCCCTAAAAAC | p.Leu40PhefsTer11 | p.L40Ffs*11 | P36871 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PGM1 | deletion | Frame_Shift_Del | novel | c.1517delA | p.Gln506ArgfsTer17 | p.Q506Rfs*17 | P36871 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
PGM1 | SNV | Missense_Mutation | | c.1233G>T | p.Trp411Cys | p.W411C | P36871 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
PGM1 | SNV | Missense_Mutation | rs201303497 | c.1366N>A | p.Ala456Thr | p.A456T | P36871 | protein_coding | deleterious(0.03) | possibly_damaging(0.786) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PGM1 | SNV | Missense_Mutation | novel | c.205N>C | p.Asp69His | p.D69H | P36871 | protein_coding | deleterious(0.01) | benign(0.015) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
PGM1 | SNV | Missense_Mutation | | c.391N>G | p.Ile131Val | p.I131V | P36871 | protein_coding | tolerated(0.22) | benign(0.168) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |